Beneran Kocak Tapi Gak Tega Ketawa: 20 Ekspresi Siswa Pas Disuntik

t MESOTHELIOMA TREATMENT E-NEWS SIGNUP Click Here to Sign Up for eNews CONTACT US Contact us here if you have any questions. (877) END-MESO (877) 363-6376 TESTIMONIALS TREATING MESOTHELIOMA There are no treatments for mesothelioma that have repeatedly provided a complete response. Any discussion of treating mesothelioma, therefore, must include a wide variety of approaches, all of which continue to be considered primarily palliative. This section also offers mesothelioma information in regards to possible post-treatment issues, recovery concerns, and coping with after-effects. TYPES OF MESOTHELIOMA TREATMENT OPTIONS Primary Mesothelioma Treatments Primary mesothelioma treatment options include some form of surgery. However, it should be noted that surgery by itself is not considered an optimal treatment process. Today mesothelioma treatments will often include surgery in conjunction with chemotherapy, radiation therapy, or both. Peritoneal Mesothelioma Treatments Peritoneal mesothelioma is found in the abdomen (on the surface of the omentum and visceral organs). Because of the complexities of this space, treatment is difficult and depending on the exact nature of the disease, treatment options are limited. Currently several treatment centers now offer peritoneal mesothelioma treatments that involve several courses of surgery over a specific interval, with chemotherapy, radiation or other treatments taking place either during or after the surgeries. Pleural Mesothelioma Treatments Forming in the pleura, the protective lining surrounding the lungs, pleura mesothelioma is often not diagnosed until it has progressed. Because the pleura is protected by the rib cage, reaching it through surgery is difficult without cutting through bone. Due to the invasiveness of these surgical procedures, treatments often include surgery in conjunction with chemotherapy and radiation. Recovering from Mesothelioma Treatment Because mesothelioma treatment is now largely multimodality, meaning it involves more than one type of treatment, recovery is often staggered over several cycles. Even diagnosis procedures, such as invasive procedures like thoracoscopy or laparoscopy, may require an extended period of recovery. When used as part of the treatment of mesothelioma, chemotherapy can also be debilitating and may include a number of serious side-effects that could require the patient to rest and recover before further treatments are resumed.

Annual Report to the Nation: overall cancer mortality continues to decline, prostate cancer mortality has stabilized Posted: May 22, 2018 Contact: NCI Press Office 240-760-6600 The latest Annual Report to the Nation on the Status of Cancer finds that overall cancer death rates continue to decline in men, women, and children in the United States in all major racial and ethnic groups. Overall cancer incidence, or rates of new cancers, decreased in men and were stable in women from 1999 to 2014. In a companion study, researchers reported that there has been an increase in incidence of late-stage prostate cancer and that after decades of decline, prostate cancer mortality has stabilized. The annual report is a collaborative effort between the National Cancer Institute (NCI), part of the National Institutes of Health; the Centers for Disease Control and Prevention (CDC); the American Cancer Society; and the North American Association of Central Cancer Registries (NAACCR). The studies appeared online in Cancer on May 22, 2018. “This year’s report is an encouraging indicator of progress we’re making in cancer research. As overall death rates continue to decline for all major racial and ethnic groups in the United States, it’s clear that interventions are having an impact,” said NCI Director Ned Sharpless, M.D. “The report also highlights areas where more work is needed. With steadfast commitment to patients and their families, we will be able to lower the mortality rates faster and improve the lives of those affected by cancer.” The report includes mortality data through 2015. It shows that, from 1999 to 2015, overall cancer death rates decreased by 1.8 percent per year among men and by 1.4 percent per year among women. From 2011 to 2015, death rates decreased for 11 of the 18 most common cancer types in men and for 14 of the 20 most common cancer types in women. Over the same period, death rates for cancers of the liver, pancreas, and brain and other nervous system increased in both men and women; death rates for cancer of the uterus increased in women; and death rates for cancers of the oral cavity and pharynx and soft tissue increased in men. From 2010 to 2014, incidence rates decreased for 7 of the 17 most common cancer types among men and for 7 of the 18 most common cancer types among women. In the companion study, researchers explored prostate cancer trends in more detail. They found that overall prostate cancer incidence rates declined an average of 6.5 percent each year between 2007 and 2014, from a rate of 163 new cases per 100,000 men in the population in 2007 to 104 new cases per 100,000 in 2014. However, incidence of distant disease—that is, of cancer that has spread from the original tumor to other parts of the body—increased from a low rate of 7.8 new cases per 100,000 in 2010 to 9.2 new cases per 100,000 in 2014. Furthermore, after two decades of decline between 1993 and 2013, prostate cancer mortality leveled off between 2013 and 2015. Although rates of distant disease increased in recent years, there was no increase in the rates of cases with aggressive histologic grade (Gleason score of 9-10). This study also reports a decline in recent prostate-specific antigen (PSA) screening in the population based on a series of national surveys. The reported decline in screening occurred between the 2010 and 2013 surveys, for men between 50 and 74 years of age, and after the 2008 survey, for men age 75 and older. “The increase in late-stage disease and the flattening of the mortality trend occurred contemporaneously with the observed decrease in PSA screening in the population,” said Serban Negoita, M.D., Dr.P.H., of NCI’s Surveillance Research Program and lead author of the prostate cancer report. “Although suggestive, this observation does not demonstrate that one caused the other, as there are many factors that contribute to incidence and mortality, such as improvements in staging and treating cancer. Additional research is needed to get a more comprehensive understanding of the recent trends and the possible relationship with PSA screening, as well as the relationship with other factors that may be associated with these trends.” Findings in the first part of the report show that incidence and death rates for all types of cancer combined were higher in men than in women in every racial and ethnic group. For all cancer sites combined, black men and white women had the highest incidence rates compared to other racial groups, and black men and black women had the highest death rates compared to other racial groups. Non-Hispanic men and women had higher incidence and death rates than those of Hispanic ethnicity. “There continue to be significant declines in the cancer death rate with significant differences in rate by sex, race, and ethnicity,” said Otis W. Brawley, M.D., chief medical officer for ACS. “We need to continue working to understand the reasons for the disparities and how to most efficiently continue supporting and, if possible, accelerate these declines.” The report also describes five-year survival during 2007-2013 by cancer stage at diagnosis for four of the most common cancers—female breast cancer, colorectal cancer, lung and bronchus cancer, and melanoma of the skin. While five-year survival is high for early-stage disease for breast cancer, colorectal cancer, and melanoma, survival remains low for all stages of lung cancer, ranging from 55 percent for Stage I to 4 percent for Stage IV. “This report underscores that if cancer is caught early, when it has the best chance of being treated, patients can live longer,” said CDC Director Robert R. Redfield, M.D. “Early detection and timely, quality treatment are keys to saving lives.” Increases in death rates for several cancers continue to cause concern. Researchers suggest that the increase in liver cancer death rates is related to the high prevalence of hepatitis C virus infection among Baby Boomers, as well as to the high prevalence of obesity in the United States. Obesity is also thought to have contributed to the increase in death rates from cancers of the uterus and pancreas. The recent increase in oral cavity and pharynx cancer death rates among white men is thought to be associated with human papillomavirus infection. “It’s encouraging to see progress in decreasing death rates for many types of cancer,” said Betsy A. Kohler, executive director, NAACCR. “Yet the fact that death rates from several cancers are still on the rise means we need to keep working to find strategies to encourage prevention and continue to make improvements in screening and treatment.” To view the full report, see: https://onlinelibrary.wiley.com/doi/abs/10.1002/cncr.31551Exit Disclaimer https://onlinelibrary.wiley.com/doi/abs/10.1002/cncr.31549Exit Disclaimer For more about the report, see: https://seer.cancer.gov/report_to_nation/ About the National Cancer Institute (NCI): NCI leads the National Cancer Program and NIH’s efforts to dramatically reduce the prevalence of cancer and improve the lives of cancer patients and their families, through research into prevention and cancer biology, the development of new interventions, and the training and mentoring of new researchers. For more information about cancer, please visit the NCI website at cancer.gov or call NCI’s Contact Center (formerly known as the Cancer Information Service) at 1-800-4-CANCER (1-800-422-6237). About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit nih.gov. About the Centers of Disease Control and Prevention (CDC): CDC works 24/7 protecting America’s health, safety, and security. Whether diseases start at home or abroad, are curable or preventable, chronic or acute, or from human activity or deliberate attack, CDC responds to America’s most pressing health threats. CDC is headquartered in Atlanta and has experts located throughout the United States and the world. About the American Cancer Society (ACS): ACS is a global grassroots force of 1.5 million volunteers dedicated to saving lives, celebrating lives, and leading the fight for a world without cancer. From breakthrough research, to free lodging near treatment, a 24/7/365 live helpline, free rides to treatment, and convening powerful activists to create awareness and impact, the Society is the attacking cancer from every angle. For more information go to www.cancer.orgExit Disclaimer. About the North American Association of Central Cancer Registries (NAACCR): The North American Association of Central Cancer Registries, Inc., is a professional organization that develops and promotes uniform data standards for cancer registration; provides education and training; certifies population-based registries; aggregates and publishes data from central cancer registries; and promotes the use of cancer surveillance data and systems for cancer control and epidemiologic research, public health programs, and patient care to reduce the burden of cancer in North America. For more, see naaccr.orgExit Disclaimer. References Cronin KA, Lake AJ, Scott S, et al. Annual Report to the Nation on the Status of Cancer, Part I: National Cancer Statistics. Cancer. Online May 22, 2018. DOI: 10.1002/cncr.31551 Negoita S, Feuer EJ, Mariotto A, et al. Annual Report to the Nation on the Status of Cancer, Part II: Recent Changes in Prostate Cancer Trends and Disease Characteristics. Cancer. Online May 22, 2018. DOI: 10.1002/cncr.31549 Most text on the National Cancer Institute website may be reproduced or reused freely. The National Cancer Institute should be credited as the source and a link to this page included, e.g., “Annual Report to the Nation: overall cancer mortality continues to decline, prostate cancer mortality has stabilized was originally published by the National Cancer Institute.” Please note that blog posts that are written by individuals from outside the government may be owned by the writer, and graphics may be owned by their creator. In such cases, it is necessary to contact the writer, artists, or publisher to obtain permission for reuse.

FINANCIAL ASSISTANCE FOR PATIENTS E-NEWS SIGNUP Click Here to Sign Up for eNews CONTACT US Contact us here if you have any questions. (877) END-MESO (877) 363-6376 TESTIMONIALS THE NEED A mesothelioma diagnosis is generally an emotionally-overwhelming experience. Unfortunately, often, it also takes a heavy financial toll on patients and their families. Mesothelioma treatment requires the expertise of a specialist who has extensive mesothelioma experience. Such experts are available at a limited number of centers, access to which often requires the patient to travel. Mesothelioma patients can greatly benefit from consulting with an expert. In many cases, the mesothelioma expert will be able to work with the patient’s local physicians to guide them through a more specialized treatment. The Meso Foundation believes that every patient should have the chance to be seen by an appropriate mesothelioma expert, regardless of their ability to pay. The Patient Travel Grant program was created to provide those patients with financial assistance. CRITERIA FOR PARTICIPATION One of the following criteria must be met to qualify for the travel grant: • A patient is required to travel in order to receive an expert consult on their mesothelioma diagnosis and cannot afford to do so without assistance. Repeat visits or treatment visits are not covered. • The patient has relapsed and needs to explore a new option of treatment or clinical trial and must travel to receive expert care or an expert consult. • The patient has enrolled in a treatment based clinical trial (found on clinicaltrials.gov) and must travel to their appointment, in which case each visit will be considered as a new application. GRANT AWARDS This program provides a one-time grant of up to $1,000 to cover expenses incurred by a patient (exceptions made for recurring clinical trial visits). This $1,000 grant can cover the costs of travel, lodging and meals. To receive a grant, patients are required to complete an application and document significant financial need. The grant is paid by check directly to the patient.

UNDERSTANDING "MILITARY RELEVANCE" E-NEWS SIGNUP Click Here to Sign Up for eNews CONTACT US Contact us here if you have any questions. (877) END-MESO (877) 363-6376 TESTIMONIALS Congress directs the Department of Defense (DoD) to “select medical research projects of clear scientific merit and direct relevance to military health.” We have found that this language is interpreted broadly. The Peer Reviewed Cancer Research Program (PRCRP) itself defines military relevance as research that is “responsive to the health care needs of the Armed Forces, family members of the Armed Forces, and the U.S. Veteran population.” Military relevance is a key feature of the Investigator-Initiated award and proposals must clearly explain the military relevance of the proposed research. A search of previously funded projects, and a review of their claims of military relevance, affirms that establishing this connection will not be difficult for mesothelioma investigators. The following section provides guidance and suggestions on demonstrating military relevance in your application. Previously funded research varies significantly in the degree to which projects relate, serve or involve the military and veteran communities. A complete search of previously funded research can be found at the website for the DoD Congressionally Directed Medical Research Program (CDMRP) at http://cdmrp.army.mil/search.aspx. To establish military relevance, consider including the following references: • There is an established history of asbestos exposure in military service, and elevated risk of mesothelioma in the military population. In fact, approximately one third of mesothelioma cases have been shown to involve Navy or shipyard exposures. (Butnor, Sharma, Sporn, Roggli: Malignant mesothelioma and occupational exposure to asbestos: an analysis of 1445 cases. Ann Occup Hyg 2002; 46: 150-153.) • Reinforce that the military and veteran populations are at higher risk of developing mesothelioma due to service related exposures to asbestos. Given the long latency of the disease, even if exposures are reduced, mesothelioma will continue to affect the veteran and military population for decades to come. • Collaborate and integrate your project with military and/or Veterans Affairs (VA) research laboratories and hospitals. Please note that it is strongly encouraged that you include letters of support and verification letter(s) if your submission includes the involvement of military recruits or subjects, military-controlled study materials, databases, and/or restricted facilities. If you need additional information on criteria for demonstrating military relevance, please contact the Meso Foundation directly at (703) 879-3797.